Immunotherapy and radiation for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug that boosts your immune system against cancer (PD-L1 inhibitor) combined with radiation therapy, with or without a bile acid supplement (ursodeoxycholic acid), for patients with advanced HER2-negative breast cancer. The goal is to see if this combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HER2-negative breast cancer that has come back or spread to other parts of the body.
- You have already received standard treatments for this cancer.
- You have at least one tumor that can be treated with radiation, and another tumor elsewhere that can be measured.
- You do not have serious bile duct or gallbladder problems, active infections, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug that helps your immune system (adebrelimab) plus chemotherapy, given after a focused ultrasound treatment (HIFU), for women with a specific type of breast cancer (HR+/HER2-) that has not spread beyond the breast or nearby lymph nodes. The goal is to see if this approach can shrink tumors before surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.